Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more
Mico BioMed Co. Ltd. (214610) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.315x
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has a cash flow conversion efficiency ratio of -0.315x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.13 Billion) by net assets (₩25.81 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mico BioMed Co. Ltd. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mico BioMed Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lippo Malls Indonesia Retail Trust
PINK:LPMDF
|
0.030x |
|
Tryptamine Therapeutics Ltd
AU:TYP
|
0.612x |
|
Best Agrolife Limited
NSE:BESTAGRO
|
N/A |
|
American Realty Investors Inc
NYSE:ARL
|
0.010x |
|
Sýn hf
IC:SYN
|
0.105x |
|
Unibap Space Solutions AB (publ)
F:JS8
|
N/A |
|
Herald Holdings Limited
STU:HH3
|
0.023x |
|
GMM Grammy Public Company Limited
BK:GRAMMY
|
0.020x |
Annual Cash Flow Conversion Efficiency for Mico BioMed Co. Ltd. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mico BioMed Co. Ltd. from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩25.89 Billion | ₩-10.70 Billion | -0.413x | -32.16% |
| 2023-12-31 | ₩36.33 Billion | ₩-11.36 Billion | -0.313x | +60.50% |
| 2022-12-31 | ₩17.69 Billion | ₩-14.01 Billion | -0.792x | -381.03% |
| 2021-12-31 | ₩52.26 Billion | ₩-8.60 Billion | -0.165x | +50.70% |
| 2020-12-31 | ₩55.96 Billion | ₩-18.68 Billion | -0.334x | +96.73% |
| 2019-12-31 | ₩1.02 Billion | ₩-10.43 Billion | -10.223x | -759.39% |
| 2018-12-31 | ₩5.71 Billion | ₩-6.79 Billion | -1.190x | -40.61% |
| 2017-12-31 | ₩3.42 Billion | ₩-2.89 Billion | -0.846x | +18.99% |
| 2016-12-31 | ₩3.83 Billion | ₩-3.99 Billion | -1.044x | -- |